The Trump administration is poised to announce a sweeping 100% tariff on imports of patented medicines and their active ingredients, according to a report by STAT. This move could be unveiled as early as Thursday, although specific details and timelines remain fluid. The proposed order includes provisions that allow drug manufacturers to circumvent these tariffs by entering into “most-favored nation” agreements, aligning U.S. drug prices with those in other affluent countries. Additionally, companies relocating production to the U.S. could see their tariff rate reduced to 20%, contingent upon approval from the U.S. Secretary of Health and Human Services. Notably, the tariffs will exempt various categories of drugs, including generics and specialty therapies, as designated by the HHS secretary.
In a parallel development, the FDA has granted approval to Eli Lilly’s obesity treatment, orforglipron, branded as Foundayo. This approval positions Lilly to compete directly with Novo Nordisk’s Wegovy, especially as demand for alternatives to GLP-1 injections rises. The new drug benefits from the FDA’s expedited review process, aimed at addressing national health priorities. Investors are optimistic that orforglipron could significantly boost Lilly’s growth, particularly given its more user-friendly administration compared to Wegovy, which requires strict dietary timing. As the market for obesity treatments expands, the implications of these developments could reshape competitive dynamics within the pharmaceutical industry.
Continue to STAT+ to read the full story…
Use the database as your supply chain compass →
